Noninvasive Prenatal Testing Market Set for Explosive Growth
|
By HospiMedica International staff writers Posted on 21 Jan 2014 |
|
The global noninvasive prenatal testing (NIPT) market is expected to grow more than ten-fold in the next five years. These are the latest findings of Transparency Market Research (Albany, NY, USA), a global information and research provider.
NIPT, the noninvasive genetic screening test for common chromosomal abnormalities (trisomy 21, trisomy 18, trisomy 13, monosomy X, etc.) can detect the presence of abnormalities in fetuses of pregnant women as early as 9–10 weeks of gestation, with some of the most commonly detected chromosomal aneuploidies include Down syndrome, Edwards syndrome, Patau syndrome, and monosomy X. The market is also evolving rapidly due the advantages it offers over conventional prenatal screening and diagnostic methods such as maternal serum screening, nuchal translucency (NT) scan, amniocentesis, and chorionic villus sampling (CVS). These advantages include safety, accuracy, and no risk of miscarriage.
MaterniT21 PLUS, verifi, Harmony, Panorama, NIFTY, PrenaTest, and BambniTest are currently the commercially available NIPTs, all based on the direct analysis of cell-free fetal DNA in the maternal blood. In 2012, MaterniT21 (a proprietary product of Sequenom) accounted for the largest share (36.6%) of the market in terms of revenue, owing to the fact that it was the first mover in the market place. During the forecast period 2013 to 2019, it is likely to lose some of its share due to increasing market penetration by other, aforementioned NIPTs such as Panorama and verify.
Almost every company in this market is adopting the same business model of marketing their tests via alliances with hospitals, diagnostic laboratories, and physician offices. The increasing penetration by test developers in European, Asia-Pacific, and Middle East countries indicates promising growth in the near future. Sequenom (San Diego, CA, USA), Verinata Health (Redwood City, CA, USA), Ariosa Diagnostics, and Natera (San Carols, CA, USA), are the leading companies engaged in providing noninvasive prenatal tests worldwide.
The global NIPT market was valued at USD 220 million in 2012 and is expected to grow at a compound annual growth rate (CAGR) of 37.6% from 2013 to 2019, to reach an estimated value of USD 3.62 billion by 2019. Geographically, North America was the largest regional market in 2012, with a market share of 64.5% of the total revenue generated globally, followed by Europe.
Related Links:
Transparency Market Research
Sequenom
Verinata Health
NIPT, the noninvasive genetic screening test for common chromosomal abnormalities (trisomy 21, trisomy 18, trisomy 13, monosomy X, etc.) can detect the presence of abnormalities in fetuses of pregnant women as early as 9–10 weeks of gestation, with some of the most commonly detected chromosomal aneuploidies include Down syndrome, Edwards syndrome, Patau syndrome, and monosomy X. The market is also evolving rapidly due the advantages it offers over conventional prenatal screening and diagnostic methods such as maternal serum screening, nuchal translucency (NT) scan, amniocentesis, and chorionic villus sampling (CVS). These advantages include safety, accuracy, and no risk of miscarriage.
MaterniT21 PLUS, verifi, Harmony, Panorama, NIFTY, PrenaTest, and BambniTest are currently the commercially available NIPTs, all based on the direct analysis of cell-free fetal DNA in the maternal blood. In 2012, MaterniT21 (a proprietary product of Sequenom) accounted for the largest share (36.6%) of the market in terms of revenue, owing to the fact that it was the first mover in the market place. During the forecast period 2013 to 2019, it is likely to lose some of its share due to increasing market penetration by other, aforementioned NIPTs such as Panorama and verify.
Almost every company in this market is adopting the same business model of marketing their tests via alliances with hospitals, diagnostic laboratories, and physician offices. The increasing penetration by test developers in European, Asia-Pacific, and Middle East countries indicates promising growth in the near future. Sequenom (San Diego, CA, USA), Verinata Health (Redwood City, CA, USA), Ariosa Diagnostics, and Natera (San Carols, CA, USA), are the leading companies engaged in providing noninvasive prenatal tests worldwide.
The global NIPT market was valued at USD 220 million in 2012 and is expected to grow at a compound annual growth rate (CAGR) of 37.6% from 2013 to 2019, to reach an estimated value of USD 3.62 billion by 2019. Geographically, North America was the largest regional market in 2012, with a market share of 64.5% of the total revenue generated globally, followed by Europe.
Related Links:
Transparency Market Research
Sequenom
Verinata Health
Gold Member
12-Channel ECG
CM1200B
Electric Bed
DIXION Intensive Care Bed
Hemostatic Agent
HEMOBLAST Bellows
Latest Business News
- B. Braun Acquires Digital Microsurgery Company True Digital Surgery
- CMEF 2025 to Promote Holistic and High-Quality Development of Medical and Health Industry
- Bayer and Broad Institute Extend Research Collaboration to Develop New Cardiovascular Therapies
- Medtronic Partners with Corsano to Expand Acute Care & Monitoring Portfolio in Europe
- Expanded Collaboration to Transform OR Technology Through AI and Automation
- Becton Dickinson to Spin Out Biosciences and Diagnostic Solutions Business
- Boston Scientific Acquires Medical Device Company SoniVie
- 2026 World Hospital Congress to be Held in Seoul
- Teleflex to Acquire BIOTRONIK’s Vascular Intervention Business
- Philips and Mass General Brigham Collaborate on Improving Patient Care with Live AI-Powered Insights
- Arab Health 2025 Celebrates Landmark 50th Edition
- Boston Scientific Acquires Medical Device Company Intera Oncology
- MEDICA 2024 to Highlight Hot Topics of MedTech Industry
- Start-Ups To Once Again Play Starring Role at MEDICA 2024
- Boston Scientific to Acquire AFib Ablation Company Cortex
- Hologic Acquires Gynesonics to Strengthen Existing Gynecological Surgical Business
Channels
Critical Care
view channel
AI Model Identifies AF Patients Requiring Blood Thinners to Prevent Stroke
Atrial fibrillation (AF) is the most common abnormal heart rhythm, affecting around 59 million people globally. It increases stroke risk because quivering in the upper heart chambers allows blood clots... Read more
Soft Robot Intubation Device Could Save Lives
Maintaining an open airway is one of the most critical priorities in emergency medicine, as without oxygen flow, other interventions can quickly fail. Endotracheal intubation is the gold standard but remains... Read more
Surgical Techniques
view channel
Novel Method Uses Interstitial Fluid Flow to Predict Where Brain Tumor Can Grow Next
Glioblastoma is one of the most aggressive brain cancers, with patients surviving on average only 15 months after diagnosis. Surgery and radiation can temporarily control the tumor, but the disease almost... Read more
World’s First Custom Anterior Cervical Spine Surgery Performed Using Personalized Implant
Anterior cervical fusion has been performed since the 1950s and is one of the most common spine procedures. Traditional implants are designed as one-size-fits-all, which can affect spinal alignment, healing,... Read more
Patient Care
view channel
Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care
More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more
VR Training Tool Combats Contamination of Portable Medical Equipment
Healthcare-associated infections (HAIs) impact one in every 31 patients, cause nearly 100,000 deaths each year, and cost USD 28.4 billion in direct medical expenses. Notably, up to 75% of these infections... Read more
Portable Biosensor Platform to Reduce Hospital-Acquired Infections
Approximately 4 million patients in the European Union acquire healthcare-associated infections (HAIs) or nosocomial infections each year, with around 37,000 deaths directly resulting from these infections,... Read more
First-Of-Its-Kind Portable Germicidal Light Technology Disinfects High-Touch Clinical Surfaces in Seconds
Reducing healthcare-acquired infections (HAIs) remains a pressing issue within global healthcare systems. In the United States alone, 1.7 million patients contract HAIs annually, leading to approximately... Read moreHealth IT
view channel
Printable Molecule-Selective Nanoparticles Enable Mass Production of Wearable Biosensors
The future of medicine is likely to focus on the personalization of healthcare—understanding exactly what an individual requires and delivering the appropriate combination of nutrients, metabolites, and... Read more
